Loxoribine

Loxoribine (7-Allyl-8-oxoguanosine) is a guanosine analog with anti-viral and anti-tumor activities. Loxoribine is an orally bioavailable and selective Toll-like receptor (TLR) 7 agonist[1][2][3].

Product Specifications

CAS Number

[121288-39-9]

Product Name Alternative

7-Allyl-8-oxoguanosine; RWJ 21757

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Influenza Virus; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/loxoribine.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 40 mg/mL (ultrasonic)

Smiles

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)NC3=O)=C3N(CC=C)C2=O)O1

Molecular Formula

C13H17N5O6

Molecular Weight

339.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Heil F, et al. The Toll-like receptor 7 (TLR7) -specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33 (11) :2987-97.|[2]Dzopalic T, et al. Loxoribine, a selective Toll-like receptor 7 agonist, induces maturation of human monocyte-derived dendritic cells and stimulates their Th-1- and Th-17-polarizing capability. Int Immunopharmacol. 2010 Nov;10 (11) :1428-33.|[3]Pope BL, et al. In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine) . Int J Immunopharmacol. 1992 Nov;14 (8) :1375-82.